<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122520</url>
  </required_header>
  <id_info>
    <org_study_id>FGC-20-003</org_study_id>
    <nct_id>NCT05122520</nct_id>
  </id_info>
  <brief_title>Hydrogen and Methane Breath Test Questionnaire</brief_title>
  <acronym>HMBTQ</acronym>
  <official_title>A Questionnaire to Identify Predictive Symptoms and Risk Factors for Hydrogen and Methane Breath Testing Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Functional Gut Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Functional Gut Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lactulose HMBT and Glucose HMBT are simple non-invasive tests to assess whether imbalances in&#xD;
      gut bacteria may be contributing to troublesome tummy symptoms. These imbalances in gut&#xD;
      bacteria include small intestinal bacterial overgrowth (SIBO) and excessive methane&#xD;
      production.&#xD;
&#xD;
      Recently there has been a lot of work to done by experts in the field, to ensure that&#xD;
      performance and interpretation of these tests are standardised, to help improve the clinical&#xD;
      utility of these investigations. Although there is a lot of information currently available&#xD;
      demonstrating the risk factors and symptoms associated with these conditions, there is a lack&#xD;
      of data demonstrating the factors that might lead to a positive test according to these new&#xD;
      parameters. This study aims to collect data on symptoms and medical history, in patients&#xD;
      referred for lactulose and glucose HMBT in order further improve the effectiveness of this&#xD;
      test in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">December 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine positive predictive symptoms for SIBO positive participants determined by HMBT</measure>
    <time_frame>At same time as breath test</time_frame>
    <description>Using the HMBTQ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine positive predictive symptoms for excessive methane positive participants determined by HMBT</measure>
    <time_frame>At same time as the breath test</time_frame>
    <description>Using the HMBTQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the frequency of recognised and potential risk factors in SIBO positive participants</measure>
    <time_frame>At the same time as the breath test</time_frame>
    <description>Using the HMBTQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the frequency of recognised and potential risk factors in excessive methane positive participants</measure>
    <time_frame>At the same time as the breath test</time_frame>
    <description>Using the HMBTQ</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1040</enrollment>
  <condition>Small Intestinal Bacterial Overgrowth</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients referred for Glucose and Lactulose HMBT at the Functional Gut Clinic&#xD;
        will be approached to see if they would like to take part in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is referred for and able to complete a postal Lactulose or Glucose HMBT&#xD;
             according to protocol with The Functional Gut Clinic&#xD;
&#xD;
          2. Participant has capacity to understand written English&#xD;
&#xD;
          3. Participant can communicate well with the Investigator and to comply with the&#xD;
             requirements for the entire study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anthony Hobson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Functional Gut Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Hobson</last_name>
    <phone>01613027777</phone>
    <email>anthony@thefunctionalgutclinic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sam Treadway</last_name>
    <phone>01613027777</phone>
    <email>sam.treadway@thefunctionalgutclinic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Functional Gut Clinic</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M3 4BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Hobson</last_name>
      <phone>01613027777</phone>
      <email>anthony@thefunctionalgutclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Sam Treadway</last_name>
      <email>sam.treadway@thefunctionalgutclinic.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Functional Gut Clinic</investigator_affiliation>
    <investigator_full_name>Dr Anthony Hobson</investigator_full_name>
    <investigator_title>Clinical Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

